Kornimate/medical-research-clean huggingface dataset:
explore biomarkers of motor neuron disease/frontal dementia spectrum disease in china

Conditions: Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Motor Neuron Disease

Summary: 1. to investigate the biomarkers of mnd/ftd spectrum disease 2. to explore the possible pathogenesis of mnd/ftd

motor neuron disease (mnd) is a group of disease characterized by motor neuron disorders and neurodegeneration. mnd and frontotemporal dementia (ftd) were believed to comprise a neurodegenerative disease spectrum. the prognosis of the disease spectrum varies according to the type of disease, and the diagnosis of patients is often delayed due to insufficient diagnostic biomarkers. in recent years, the academic community has made significant progress in the study of biomarkers of the disease, but there is still a lack of specific biomarkers with strong diagnostic value. besides, the low prevalence makes it difficult to carry out studies with large samples. the aim of this study was to explore diagnostic biomarkers of the disease spectrum by collecting variable samples from a large group of patients. the findings will both offer a better understanding of mnd/ftd spectrum disease and also support the development of a model to study other rare diseases.

Eligibility criteria:
patients: inclusion criteria: 1. patients aged 18-80 years who visit peking university third hospital, beijing, china from december 2020. patients who diagnosis mnd/ftd spectrum disease (including als, fas, fls, pls, pbp, pma, ftd, mnd-ftd) by an experienced neurologist strictly according to a list of diagnosis criteria and clinical guidelines 2. informed consent signed exclusion criteria * patients who receive alternative diagnoses during the follow-up. * patients who refuse to sign informed consent. control group: control group consists of individuals matched for gender and age with the patients who are mainly the caregivers of the patients, including but not limited to the patients' spouses and their long-term nurses. exclusion criteria: 1. suffering from neurological disease, including but not limited to motor neuron disease/frontotemporal dementia spectrum disease, dementia, alzheimer's disease, parkinson's disease, multiple sclerosis, neuromyelitis and so on. 2. individuals who refuse to sign informed consent.
ibrutinib for relapsed or refractory mantle cell lymphoma

Conditions: Mantle Cell Lymphoma

Summary: to review the efficacy and the safety of ibrutinib in patients with relapsed or refractory mantle cell lymphoma (mcl).

# background and rationale mantle cell lymphoma (mcl) is a rare subtype of lymphoma, accounting for about 3-6% of all non-hodgkin's lymphoma. it is clinically prevalent in the elderly and men, commonly with gastrointestinal tract involvement. since about 80% of patients present with advanced stage disease at diagnosis, the prognosis is very poor. mantle cell lymphoma is less frequent in korean than in western countries, accounting for about 2% of all non-hodgkin's lymphoma cases, with very poor treatment outcome as western countries. in korea, the clinical information about patients with mcl is very scarce so far and does not reflect recent treatment patterns. firstly, the incidence in korea is relatively lower than that in western countries, with only about 100 patients a year. secondly, due to substandard national health insurance regulations in korea, it was not until recently that ibrutinib for relapsed/refractory mcl was approved for coverage by the national health insurance. in this context, the study was designed to investigate the efficacy and safety of ibrutinib in patients with relapsed or refractory mcl in korea.

Eligibility criteria:
inclusion criteria: * patients with mcl diagnosed by a pathologist (based on the who 2017 classification) 1. mantle cell lymphoma 2. leukemic nonnodal mantle cell lymphoma 3. in situ mantle cell neoplasia * aged ≥ 19 years * relapsed or refractory patients treated with ibrutinib, including relapse after autologous stem cell transplantation exclusion criteria: * patients whose clinical and pathological data are not available * patients who were not treated with ibrutinib
aminophylline infusion on pain intensity after ureterocopic lithotripsy

Conditions: Aminophylline; Pain; Ureterocopic Lithotripsy

Summary: this study will be conducted to evaluate the effect of intraoperative systemic aminophylline infusion on pain intensity in patients undergoing ureteroscopic lithotripsy surgeries with ureteric stent placement at the end of the procedure.


Eligibility criteria:
inclusion criteria: * aged between 18 to 50 years * american society of anesthesiology (asa) physical status i - ii * body mass index (bmi) less than 30.0 kg/m2 * scheduled for ureteroscopic lithotripsy surgery with d-j ureteric stent placement at the end of procedure * under general anesthesia. exclusion criteria: 1. patients with central nervous system diseases, cardiovascular diseases, arrhythmias, cerebrovascular diseases, convulsions, renal impairment or hepatic dysfunction. 2. pregnancy or lactation. 3. patients with a history of allergy to aminophylline. 4. coffee consumption (more than 2 cups/day) 5. patients with opioid addiction or patients treated with b agonists, tranquilizers, or antidepressants. 6. short procedures less than 30 minutes or procedures not requiring d-j stent placement.

Keywords: aminophylline postoperative pain ureterocopic lithotripsy
cryoablation of small breast tumors in early stage breast cancer

Conditions: Breast Cancer

Summary: this study examines the use of cryoablation as an alternative to surgery in the treatment of early stage invasive breast cancer. the hypothesis is that cryoablation will complete ablation and destroy the tumor in a selected population of women who may otherwise be adequately treated with surgery.

purpose: to determine the rate of successful tumor ablation in patients treated with cryoablation and endocrine therapy in a subset of patients with early stage breast cancer. outline: 1. core biopsy (pre-registration) 2. magnetic resonance imaging (pre-registration) 3. tumor cryoablation 4. core biopsy (post-cryoablation) 5. magnetic resonance imaging (post-cryoablation) 6. postoperative follow-up 7. evaluation of outcomes

Eligibility criteria:
inclusion criteria: 1. age ≥ 50 2. unifocal primary invasive breast carcinoma diagnosed by core needle biopsy 3. maximum tumor size ≤1.5 cm in its greatest diameter 4. ultrasound visible lesion(s) 5. clinically node negative, hormone receptor positive (+). her2 negative (-), with \<25% intraductal component in the aggregate. 6. unilateral or bilateral disease meeting study criteria 7. physical and emotional ability to undergo baseline and follow-up breast mris and serial breast cosmesis analysis 8. patient agrees to receive a 5 year minimum course of endocrine therapy following cryoablation for control of systemic disease exclusion criteria: 1. prior treatment (e.g., open surgical biopsy, lumpectomy) of index cancer 2. ductal carcinoma in-situ with microinvasions (t1mic) 3. multifocal or multicentric invasive breast carcinoma 4. prior or planned neoadjuvant systemic therapy for breast cancer 5. tumor with ≥25% idc components

Keywords: cryoablation
single vs. two implants for mandibular overdentures

Conditions: Bleeding on Probing; Alveolar Bone Loss; Mastication; Dental Plaque; Periodontal Index

Summary: this study aimed to compare the use of single implants in the symphyseal and parasymphyseal, and two implants were inserted in the canine area bilaterally to assist mandibular complete overdentures regarding clinical evaluation, marginal bone loss, and masticatory efficiency. the null hypothesis was that there was no statistically significant difference in clinical evaluation, marginal bone loss, and masticatory efficiency among single symphyseal implants, single parasymphyseal implants, and two-implant-assisted complete mandibular overdentures.

this randomized, controlled clinical trial compared the symphyseal and parasymphyseal single implants versus two implants in complete mandibular overdentures. fifteen completely edentulous male patients (50-65 years) were chosen and randomly grouped into three equal groups (five patients in each) according to the position and number of the received implants to assist mandibular complete overdentures. group i: single median implant. group ii: single parasymphyseal implant. group iii: two implants were inserted in the canine area bilaterally. after three months of osseointegration, the lower denture was transformed into an implant-assisted complete mandibular overdenture. clinical observations were documented on the day of loading, three, six, and nine months later for each implant. follow-up cbct scans were performed to assess marginal bone loss on the day of loading, six and twelve months later. the masticatory efficiency evaluation was conducted one month and three months after loading.

Eligibility criteria:
inclusion criteria: * patients with a class i maxillo-mandibular jaw relationship * patients with residual ridges had normal morphology, were free from severe bony undercuts or flabby tissue, and were covered by firm mucoperiosteum. * a cone beam ct of the lower arch was made to detect the presence of pathological lesions, remaining roots, or impacted teeth in the arch and evaluate both bone quality and quantity, especially in the area of interest exclusion criteria: * patients with current chemotherapy or radiotherapy, bleeding disorders, uncontrolled diabetes * patients with a history of drug therapy that interferes with bone resorption or deposition (e.g., the prolonged use of glucocorticoids, antiresorptive medications, selective serotonin reuptake inhibitors, and proton-pump inhibitors), * those with any physical reasons that could affect follow-up, psychiatric problems, heavy smokers, drug or alcohol addicts, immunocompromised patients, abnormal jaw relationship, inadequate inter arch space. * patients with temporomandibular disorders and para-functional habits (e.g., bruxing and clenching).
rectal indomethacin to prevent post-ercp pancreatitis

Conditions: Post-ERCP Acute Pancreatitis

Summary: acute pancreatitis is the most common and feared complication of ercp, occurring after 1% to 30% of procedures. since 2012, a multicenter rct was published in nejm, indomethacin use in high risk patients was considered a "standard" method to prevent pep. however, the risk factors of pep is not fully clear. rectal indomethacin before ercp for all patients, not just for selected high-risk patients, may preventing pep maximum. the purpose of this study is to determine whether routine using of rectal indomethacin is more effective than the conditional strategy.


Eligibility criteria:
inclusion criteria: * patients undergoing diagnostic or therapeutic ercp. exclusion criteria: * unwillingness or inability to consent for the study; * age \< 18 years old; * intrauterine pregnancy; * breastfeeding mother; * standard contraindications to ercp; * allergy to nsaids; * received nsaids in prior 7 days; * renal failure (cr \>1.4mg/dl=120umol/l); * active or recurrent (within 4 weeks) gastrointestinal hemorrhage; * acute pancreatitis within 72 hours; * known pancreatic head mass; * subject with prior biliary sphincterotomy now scheduled for repeat biliary therapy without anticipated pancreatogram; * ercp for biliary stent removal or exchange without anticipated pancreatogram; * known active cardiovascular or cerebrovascular disease. * presence of coagulopathy before the procedure or received anticoagulation therapy within three days before the procedure;

Keywords: indomethacin, pancreatitis, ercp
general psychological distress, ptsd, and co-morbidities in healthcare workers consequent to covid-19

Conditions: Post-traumatic Stress Disorder; Moral Injury

Summary: it is expected that large numbers of healthcare workers will experience a broad range of psychological reactions and symptoms including anxiety, depression, moral distress, and trauma symptoms that will cause both significant suffering as well as occupational and social impairment. the purpose of this study is to find interventions which are helpful in treating psychological distress in healthcare workers caring for covid-19 patients. there are two phases of the study. all participants will take part in phase i, which consists of 4 sessions over a two-week period of either a narrative writing intervention or a medical music intervention. participants will be randomly assigned to the narrative writing intervention or medical music intervention. after phase i, participants will be re-assessed. healthcare workers who meet criteria for ptsd will be given the option to participate in phase ii of the study, in which they will be offered a choice between one of two evidence-based treatments for ptsd: interpersonal therapy (ipt) or exposure therapy (et). both treatments are comprised of ten 75-minute sessions scheduled twice weekly. participants will be allowed to choose a preferred treatment in phase ii. after phase ii participants will complete a final assessment concluding the study. all interventions will be offered using distance technology.


Eligibility criteria:
inclusion criteria: * any healthcare worker providing medical care or support for covid-19 patients * english-speaking * age \>18 * medically stable * able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments * if on psychotropic medication stable for prior 60 days for phase ii additional inclusion criteria: - current diagnosis of ptsd exclusion criteria: * current significant unstable medical illness precluding regular session attendance or assessment completion * participants who in the investigator's judgment pose a current homicidal, suicidal, or other risk * lifetime or current diagnosis of schizophrenia or other psychotic disorder * participation in a clinical trial or concurrent evidence-based treatment for psychiatric conditions or ptsd during the previous 3 months.

Keywords: ptsd moral injury psychological distress healthcare workers covid-19 covid-19 pandemic
oral enteral nutrition feeding in alzheimer's patients

Conditions: Alzheimer Disease

Summary: this is a prospective multicenter study with alzheimer's patients with dysphagia. patients enrolled are randomly divided equally into the observation group and the control group. all patients receive conventional care, and the observation group received intermittent oral-esophageal tube feeding while the control group received nasogastric tube feeding for enteral nutrition support. baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life after treatment are compared.

the alzheimer's disease in the elderly exhibits the high prevalence.this is a prospective multicenter study with alzheimer's patients with dysphagia. patients enrolled are randomly divided equally into the observation group and the control group. all patients receive conventional care, and the observation group received intermittent oral-esophageal tube feeding while the control group received nasogastric tube feeding for enteral nutrition support. baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life after treatment are compared.

Eligibility criteria:
inclusion criteria: * age between 18 years and 85 years, meeting the diagnosis of alzheimer's disease. * presence of no contraindication for enteral nutrition. * with dysphagia verified by imaging materials. * with stable vital signs and no severe liver or kidney dysfunction, metabolic disorders, cardiovascular diseases, or multiple complications * minimum mental state examination ranging from 10-26 exclusion criteria: * unable to cooperate in completing treatment and assessment due to personal reasons or other disorders. * complicated with other intracranial lesions, such as stroke. * abnormal structure of swallowing-related organ and tissue.
a dose escalating study of sgx942 for oral mucositis in patients with head and neck cancer

Conditions: Oral Mucositis

Summary: to evaluate the safety and efficacy of sgx942 in patients receiving chemoradiation treatment for the treatment of head and neck cancer.


Eligibility criteria:
inclusion criteria: * biopsy-proven non-metastatic squamous cell carcinoma of the mouth or oropharynx and is planned to receive a standard course of concomitant crt. * patients who have received surgery are eligible if surgery is performed within 6 weeks prior to study initiation. * planned to receive standard cisplatin chemotherapy administered either weekly or every third week. * must be able to read and understand informed consent * adequate birth control methods for the duration of the study exclusion criteria: * current mucositis. * prior radiation to the head and neck. * chemotherapy treatment within the previous 12 months. * tumors of the lips, sinuses, salivary glands or nasopharynx. * unknown primary tumor. * stage 4c metastases. * evidence of significant hepatic, hematologic, or immunologic disease. * women who are pregnant or breast-feeding.
an investigation to identify subjects admitted to hospital with an increased risk of developing pressure ulcers

Conditions: Pressure Ulcer

Summary: a double blind, non randomized, multicenter investigation

the study consists of 2 evaluations/visits. evaluation/visit 1: takes place in connection with admission to the hospital. informed consent, inclusion and exclusion criteria are assessed as well as assessment of skin type and inspection of the entire body skin. pregnancy test on women of childbearing potential, height, weight, blood pressure and body temperature are measured. questions about demography, health conditions, previous illnesses, nicotine habits. risk assessment for pressure ulcers (modified norton or raps-scale) is carried out according to the hospital usual routine. examination with pu sensor will be performed. evaluation/visit 2: takes place in connection with the discharge from the hospital or 4 weeks after visit 1 if the research subject is still hospitalized. full body skin inspection to see possible onset of pressure ulcers. review of the research subject's medical records as well as review of nursing notes from the hospital where the research subject has been discharged from, to find any notes about pressure ulcers. the study participation is then terminated for the research subject.

Eligibility criteria:
inclusion criteria: 1. given their written consent to participate in the study 2. male or female between ≥18 years and ≤ 64 years with a reduced mobility, where the hospitalization may involve a risk that the person may become less active or male or female ≥65 years exclusion criteria: 1. existing pressure ulcer or damage to the skin around the sacrum where the pu sensor plate and pillow are to be placed 2. fever ≥38 ºc, within 30 minutes before the examination with pu sensor 3. difficulty lying still in supine position during the examination with pu sensor, which takes 5 to 10 minutes 4. known allergy or sensitivity to any of the materials in pu sensor that gets in contact with the skin on the sacrum 5. body weight ≥200 kg 6. previous participation in the study 7. mental inability, or language difficulties that results in difficulty to understand the meaning of participation in the study and / or signing the study consent, 8. pregnancy
study of paclitaxel plus cisplatin as the first-line chemotherapy in high risk gestational trophoblastic tumor

Conditions: Gestational Trophoblastic Neoplasms

Summary: this clinical trial is designed to study the effect and safety of paclitaxel plus cisplatin as the first-line regimen in the treatment of high risk gestational trophoblastic tumor.

gestational trophoblastic tumor (gtn) is a group of malignant tumors derived from placental trophoblastic cells, most of which occur in women of reproductive age. the survival rate of patients with score of 7 or more points, or who ⅳ period for high-risk patients was of 60% to 80%. however, due to severe toxic reactions, long treatment time, loss of optimal reproductive age and increased costs, and treatment failure caused by chemotherapy resistance, high-risk gtn is still one of the tumors seriously affecting the life health and quality of life of young women. first-line chemotherapy recommended by figo is regimen of ema - co with corresponding side effects and adverse factors in the following aspects as relatively higer incidence of myelosupression, vp - 16 being associated with a second tumor, especially leukemia, and a definite effect of cyclophosphamide on the failure ovarian function taxol (taxol) is the most widely used and most effective broad-spectrum anti-tumor drug in gynecological malignant tumors at present, and t (paclitaxel) +p (platinum drugs) scheme is the first-line chemotherapy scheme in ovarian cancer patients at present. according to references, tp also has effects on resistant and refactory high risk gtn patients. given relatively simple operation way of tp chemotherapy, and the effect of chemotherapy in recurrence and high-risk refractory gtn performance,this prospective multicenter randomized controlled clinical research was to study the effect and safety of paclitaxel plus cisplatin as the first-line regimen in the treatment of high risk gestational trophoblastic tumor compared with ema-co.

Eligibility criteria:
inclusion criteria: * patients who international federation of gynecology and obstetrics (figo) stage i, ii, or iii criteria for high-risk gestational trophoblastic neoplasia (gtn) and stage ⅳ cases * world health organization(who) risk score ≥7, and less than 13 * age≤60 years; female, chinese women * initial treatment is chemotherapy * performance status: karnofsky score≥60 * laboratory tests: wbc≥3.5×10(9)/l, anc≥1.5×10(9)/l, plt≥80×10(9)/l, serum bilirubin≤ 1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of normal,blood urea nitrogen, cr≤ normal * provide written informed consent. exclusion criteria: * patients with unconfirmed diagnosis of gtn * patients with placental-site trophoblastic tumor (pstt) or epithelioid trophoblastic tumor (ett) * who risk score less than 7 * with severe or uncontrolled internal disease, unable to receive chemotherapy * concurrently participating in other clinical trials * unable or unwilling to sign informed consents * unable or unwilling to abide by protocol

Keywords: gestational trophoblastic tumor paclitaxel cisplatin carboplatin chemotherapy